Clinical Trial Update: The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety of administering a second dose of a COVID-19 mRNA vaccine in individuals who had a systemic allergic reaction to the initial dose…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Allergic Reaction Following Vaccination

Drugs mentioned

• COVID-19 mRNA vaccine (second dose safety study)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Systemic Allergic Reaction | Phase 2 | Status: COMPLETED | Results posted: 2023-10-16